(18 days)
Not Found
No
The device description and performance studies focus on standard quality control materials for a hematology system, with no mention of AI or ML algorithms for analysis or interpretation.
No
The device is a hematology reference material for quality control of a diagnostic system, not intended for treating patients.
No
This device is a control material used to monitor the precision and accuracy of another diagnostic system (ADVIA 120 Hematology System), rather than directly diagnosing a patient's condition.
No
The device is a physical control material (assay control mixture) composed of biological components (red and white blood cells) in a stabilizing medium, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that it is for "monitoring the precision and accuracy of the ADVIA 120 Hematology System when analyzing CSF samples." This indicates it's used in a laboratory setting to evaluate the performance of a diagnostic instrument.
- Device Description: The description clarifies that it is an "assay control mixture used for quality control of the ADVIA 120 CSF (cerebral spinal fluid) method." Quality control materials for diagnostic assays are a key component of IVD testing.
- Nature of the Material: The control materials are composed of biological components (red blood cells and white blood cells) derived from human sources, which are used to simulate patient samples for testing purposes.
- Predicate Device: The predicate device listed is "Cell-Chex body fluid controls," which are also IVD controls used for similar purposes.
Based on these points, the ADVIA TESTpoint CSF Controls clearly fit the definition of an In Vitro Diagnostic device. They are used outside of the body to provide information about the performance of a diagnostic test.
N/A
Intended Use / Indications for Use
ADVIA TESTpoint CSF Controls are hematology reference materials for monitoring the precision and accuracy of the ADVIA 120 Hematology System when analyzing CSF samples.
Product codes (comma separated list FDA assigned to the subject device)
JPK
Device Description
ADVIA TESTpoint CSF Controls is an assay control mixture used for quality control of the ADVIA 120 CSF (cerebral spinal fluid) method. The control materials are composed of red blood cells and white blood cells derived from human sources stored in a stabilizing medium. The control materials consist of two levels that simulate a low cell count (Level 1) and a higher abnormal count (Level 2).
The following RBC and WBC parameters are reportable with the control materials:
Level 1 WBC - white blood cell count RBC - red blood cell count
Level 2
WBC - white blood cell count RBC - red blood cell count % Neut – percent neutrophil count % Lymph - percent lymphocyte count % Mono - percent monocyte count % Eos - percent eosinophil count % MN - percent mononuclear cell count % PMN - percent polymorphonuclear cell count
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The test results included in this submission demonstrate that the ADVIA TEST point CSF Controls are substantially equivalent to the predicate device. The control materials have demonstrated acceptable precision as observed by the minimal variability (SD and %CV) found in stability testing, and meets the manufacturer's intended specifications for both shelf life and open vial stability.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.8625 Hematology quality control mixture.
(a)
Identification. A hematology quality control mixture is a device used to ascertain the accuracy and precision of manual, semiautomated, and automated determinations of cell parameters such as white cell count (WBC), red cell count (RBC), platelet count (PLT), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC).(b)
Classification. Class II (special controls). Except when intended for use in blood components, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
SEP 2 4 2002
510(k) Summary of Safety and Effectiveness
The following information provides data supporting a substantially equivalent determination for the ADVIA TESTpoint CSF Controls.
Predicate Device
Cell-Chex body fluid controls manufactured by Streck Laboratories, Inc (K000076).
Intended Use
ADVIA TEST ontrols are hematology reference materials for monitoring the precision and accuracy of the ADVIA 120 Hematology System when analyzing CSF samples.
Device Description
ADVIA TESTpoint CSF Controls is an assay control mixture used for quality control of the ADVIA 120 CSF (cerebral spinal fluid) method. The control materials are composed of red blood cells and white blood cells derived from human sources stored in a stabilizing medium. The control materials consist of two levels that simulate a low cell count (Level 1) and a higher abnormal count (Level 2).
The following RBC and WBC parameters are reportable with the control materials:
Level 1 WBC - white blood cell count RBC - red blood cell count
Level 2
WBC - white blood cell count RBC - red blood cell count % Neut – percent neutrophil count % Lymph - percent lymphocyte count % Mono - percent monocyte count % Eos - percent eosinophil count % MN - percent mononuclear cell count % PMN - percent polymorphonuclear cell count
Comparison with Predicate Device
The following table provides similarities and differences between ADVIA TESTpoint CSF Controls and the predicate device (K000076).
1
| Predicate | ADVIA TESTpoint | ||
|---|---|---|---|
| Similarities/Differences | Characteristic | Device | CSF Controls |
| Similarities | Intended Use | Quality control material | |
| for control of | |||
| cerebrospinal fluid cell | |||
| counts. | Same as predicate | ||
| device. | |||
| Control | |||
| Composition | Human red blood cells | ||
| and human white blood | |||
| cells in a preservative | |||
| medium. | Similar to | ||
| predicate device. | |||
| Targeted | |||
| Control Ranges | Level 1 – Low cell count | ||
| Level 2 - High abnormal | |||
| cell count | Similar to | ||
| predicate device. | |||
| Differences | Intended Use | Intended to control | |
| manual cell counts. | Intended to control | ||
| ADVIA 120 | |||
| automated cell | |||
| counts. | |||
| Level 1 WBC | |||
| Differential | Two part WBC | ||
| Differential | No WBC | ||
| Differential on | |||
| Level 1 | |||
| Level 2 WBC | |||
| Differential | Two part WBC | ||
| Differential | Five part WBC | ||
| Differential |
Conclusion
The test results included in this submission demonstrate that the ADVIA TEST point CSF Controls are substantially equivalent to the predicate device. The control materials have demonstrated acceptable precision as observed by the minimal variability (SD and %CV) found in stability testing, and meets the manufacturer's intended specifications for both shelf life and open vial stability.
Kuu-deff. Oks
Date 9/05/02
Kenneth T. Edds, Ph.D. Manager, Regulatory Affairs Bayer Corporation 511Benedict Avenue Tarrytown, New York 10591-5097
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized image of three human figures, represented by curved lines, symbolizing health and well-being.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
SEP 2 4 2002
Kenneth T. Edds, Ph.D. Manager, Regulatory Affairs Bayer Diagnostics 511 Benedict Avenue Tarrytown, NY 10591-5097
Re: K022968
Trade/Device Name: ADVIA TESTpoint CSF Controls Regulation Number: 21 CFR 864.8625 Regulation Name: Hematology Quality Control Mixture Regulatory Class: Class II Product Code: JPK Dated: September 6, 2002 Received: September 6, 2002
Dear Dr. Edds:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
K022968 510(k) Number:
Device Name: ADVIA TESTpoint CSF Controls
Indications for Use: ADVIA TESTpoint CSF Controls are hematology reference materials for monitoring the precision and accuracy of the ADVIA 120 Hematology System when analyzing CSF samples.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-CounterUse
(Optional Format 1-2-96)
Josephine Butler
Division Sign of Clinical Laborator 510(k) Number